Edition:
United Kingdom

Rigel Pharmaceuticals Inc (RIGL.OQ)

RIGL.OQ on NASDAQ Stock Exchange Global Select Market

3.35USD
25 Sep 2018
Change (% chg)

$0.05 (+1.52%)
Prev Close
$3.30
Open
$3.29
Day's High
$3.37
Day's Low
$3.29
Volume
65,578
Avg. Vol
654,800
52-wk High
$4.71
52-wk Low
$2.29

Chart for

About

Rigel Pharmaceuticals, Inc., is a clinical-stage biotechnology company. The Company is engaged in discovering, developing and providing novel small molecule drugs that improve the lives of patients with immune and hematological disorders, cancer and rare diseases. The Company’s research focuses on signaling pathways that are... (more)

Overall

Beta: 1.16
Market Cap(Mil.): $482.64
Shares Outstanding(Mil.): 124.39
Dividend: --
Yield (%): --

Financials

  RIGL.OQ Industry Sector
P/E (TTM): -- 85.68 32.76
EPS (TTM): -0.69 -- --
ROI: -98.94 1.79 14.61
ROE: -101.42 3.28 16.33

BRIEF-Rigel Pharmaceuticals Q1 Loss Per Share $0.17

* RIGEL ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE

01 May 2018

BRIEF-Rigel Pharmaceuticals Says Expects To Report About $94.3 Mln Cash, Cash Equivalents, Short-Term Investments As Of March 31, 2018

* RIGEL PHARMACEUTICALS SAYS EXPECTS TO REPORT IT HAD ABOUT $94.3 MILLION CASH, CASH EQUIVALENTS, SHORT-TERM INVESTMENTS AS OF MARCH 31, 2018 - SEC FILING Source text: (https://bit.ly/2Jedbsn) Further company coverage:

20 Apr 2018

BRIEF-Rigel Announces Pricing Of Public Offering Of Common Stock

* PUBLIC OFFERING OF 16,000,000 SHARES OF ITS COMMON STOCK, OFFERED AT A PRICE OF $3.90 PER SHARE TO PUBLIC Source text for Eikon: Further company coverage:

20 Apr 2018

BRIEF-Rigel Intends To Offer & Sell Up To 15 Mln Shares Of Its Stock In Underwritten Public Offering

* RIGEL PHARMACEUTICALS INC - INTENDS TO OFFER & SELL UP TO 15 MILLION SHARES OF ITS STOCK IN AN UNDERWRITTEN PUBLIC OFFERING

18 Apr 2018

BRIEF-Rigel Pharmaceuticals NDA For Tavalisse Approved By FDA

* RIGEL PHARMACEUTICALS NDA FOR TAVALISSE APPROVED BY FDA Source text: (http://bit.ly/2HGn96a) Further company coverage:

17 Apr 2018

FDA approves Rigel Pharmaceuticals' drug for rare bleeding disorder

The U.S. Food and Drug Administration on Tuesday approved Rigel Pharmaceuticals Inc's treatment for a rare bleeding disorder.

17 Apr 2018

FDA approves Rigel Pharmaceuticals' drug for rare bleeding disorder

April 17 The U.S. Food and Drug Administration on Tuesday approved Rigel Pharmaceuticals Inc's treatment for a rare bleeding disorder.

17 Apr 2018

BRIEF-Rigel Makes Statement Regarding Website Error

* FDA IS CONTINUING ITS REVIEW OF NDA AND PDUFA ACTION DATE FOR FOSTAMATINIB NDA IS APRIL 17

12 Apr 2018

REFILE-BRIEF-Rigel Announces Topline Data From Phase 2 Study Of Fostamatinib

* RIGEL ANNOUNCES TOPLINE DATA FROM PROOF-OF-CONCEPT PHASE 2 STUDY OF FOSTAMATINIB IN IGA NEPHROPATHY

03 Apr 2018

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF83.18 +1.38
Roche Holding Ltd. (ROG.S) CHF236.15 +3.15
Roche Holding Ltd. (RO.S) CHF237.00 +3.00
Merck & Co., Inc. (MRK.N) $70.65 -0.13
Sanofi SA (SASY.PA) €74.61 --
AstraZeneca plc (AZN.L) 5,793.00 +141.00
Abbott Laboratories (ABT.N) $72.20 +0.76

Earnings vs. Estimates